Cited by 1,192Diabetes Treatment and ManagementDiabetes Management and ResearchHeart Failure Treatment and Management

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Open access

Buse, John B., Wexler, Deborah J., Tsapas, Apostolos, Rossing, Peter, Mingrone, Geltrude, Mathieu, Chantal, D’Alessio, David A., Davies, Melanie J.·2020·Diabetes Care

DOI 10.2337/dci19-0066PMC PMC6971782

Open this paper in CoChat — free account Open PDF

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dci19-0066

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citation
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“Somemeta-analyses (5,13,14) suggest the presence of heterogeneity in estimates forMACE andCVdeathwithGLP-1 receptor agonists, although this ismostly due to the results of a single trial with lixisenatide.”
Result
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citation
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084

Flagged first, then by citations

Show all 21 references

Sorted by citations

Items 401–500 of 1,000

Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis
Liu, T., Fan, Z., Xiao, B., Chang, H., & Wang, S. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02200-7 · Cited by 16
Investigation of the Systemic Immune Inflammation (SII) Index as an Indicator of Morbidity and Mortality in Type 2 Diabetic Retinopathy Patients in a 4-Year Follow-Up Period
Tabakoğlu, N. T., & Çelik, M. (2024) · Medicina · doi:10.3390/medicina60060855 · Cited by 20
Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes
Lou, Y., Xu, Y.-L., Xiong, Y., Deng, C., & Wang, Q. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01475-7 · Cited by 16
Glucagon-like peptide-1 receptor agonists or sodium–glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints
Patoulias, D., Katsimardou, A., Kalogirou, M., Zografou, I., Toumpourleka, M., Imprialos, K. P., Stavropoulos, K., Stergiou, I., Papadopoulos, C. E., & Doumas, M. N. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.04.001 · Cited by 15
Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial
Kadowaki, T., Wang, G., Rosenstock, J., Yabe, D., Peng, Y., Kanasaki, K., Mu, Y., Mattheus, M., Keller, A., Okamura, T., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00447-5 · Cited by 16
Efficacy and safety of patient-led versus physician-led titration of basal insulin in patients with uncontrolled type 2 diabetes: a meta-analysis of randomized controlled trials
Castellana, M., Procino, F., Sardone, R., Trimboli, P., & Giannelli, G. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001477 · Cited by 16
Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
Sumida, Y., Yoneda, M., Toyoda, H., Yasuda, S., Tada, T., Hayashi, H., Nishigaki, Y., Suzuki, Y., Naiki, T., Morishita, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144939 · Cited by 16
Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions
Lefever, E., Vliebergh, J., & Mathieu, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1856813 · Cited by 16
Self-citation
Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Zhang, A., Luo, X., Meng, H., Kang, J., Qin, G., Chen, Y., & Zhang, X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.604250 · Cited by 16
Genetically Guided Mediterranean Diet for the Personalized Nutritional Management of Type 2 Diabetes Mellitus
Gkouskou, K. K., Lazou, E., Skoufas, E., & Eliopoulos, A. G. (2021) · Nutrients · doi:10.3390/nu13020355 · Cited by 19
Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain
Lima, A. O. D. L., Castro, Ó. D., Romero-Requena, J. M., Díaz-Guerra, M. D. L. R. G., Pineda, V. A., Diaz, M., Ascanio, M., Darbà, J., & Cruzado, J. M. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab076 · Cited by 16
The impact of diabetes on heart failure development: The cardio-renal-metabolic connection
Valensi, P. E., Prévost, G., Pinto, S., Halimi, J., & Donal, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108831 · Cited by 18
Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021)
Dashora, U. K., Gregory, R., Winocour, P. H., Dhatariya, K., Rowles, S. V., Macklin, A., Rayman, G. A., Nagi, D. K., Whitehead, K., Beba, H., et al. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0045 · Cited by 17
Long-term glycemic variability and risk of stroke in patients with diabetes: a meta-analysis
Ren, X., Wang, Z., & Guo, C. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00770-0 · Cited by 16
Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin
Sattar, N. A., & McGuire, D. K. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa879 · Cited by 16
DIABETES AND RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM: IMPLICATIONS FOR COVID-19 PATIENTS WITH DIABETES TREATMENT MANAGEMENT
Catrinoiu, D. (2020) · FARMACIA · doi:10.31925/farmacia.2020.3.1 · Cited by 17
Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM
Li, L.-F., Ding, L., Zhan, Z., & Qiu, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.690529 · Cited by 15
Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies
Casale, M., Baldini, M., Monte, P. D., Gigante, A., Grandone, A., Origa, R., Poggi, M., Gadda, F., Lai, R., Marchetti, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071826 · Cited by 15
Characteristics of Cognitive Impairment and Their Relationship With Total Cerebral Small Vascular Disease Score in Parkinson’s Disease
Hou, M., Hou, X., Qiu, Y., Wang, J., Zhang, M., Mao, X., & Wu, X. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.884506 · Cited by 15
Recent Progress in the Diagnosis and Management of Type 2 Diabetes Mellitus in the Era of COVID-19 and Single Cell Multi-Omics Technologies
Kupai, K., Várkonyi, T. T., Török, S., Gáti, V., Czimmerer, Z., Puskás, L. G., & Szebeni, G. J. (2022) · Life · doi:10.3390/life12081205 · Cited by 17
GLP-1 receptor agonists modulate blood glucose levels in T2DM by affecting Faecalibacterium prausnitzii abundance in the intestine
Liang, L., Rao, E., Zhang, X., Wu, B., Su, X., Chen, L., Nie, R., & Nian, X. (2023) · Medicine · doi:10.1097/md.0000000000034978 · Cited by 15
Barriers and Enablers for Deprescribing Glucose-Lowering Treatment in Older Adults: A Systematic Review
Mellot, M., Jawal, L., Morel, T., Fournier, J., Tubach, F., Cadwallader, J., Christiaens, A., & Zerah, L. (2024) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2023.11.025 · Cited by 15
Number needed to treat in cardiovascular outcome trials of glucagon‐like peptide‐1 receptor agonists: A systematic review with temporal analysis
Davies, M. J., Kloecker, D. E., Webb, D. R., Khunti, K. K., & Zaccardi, F. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14066 · Cited by 15
Self-citation
Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease
Escott, G. M., da Silveira, L. G., Cancelier, V. D. A., Dall’Agnol, A., & Silveiro, S. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107774 · Cited by 16
Switching to Versus Addition of Incretin‐Based Drugs Among Patients With Type 2 Diabetes Taking Sodium‐Glucose Cotransporter‐2 Inhibitors
Lau, K. T. K., Wong, C. K. H., Au, I. C. H., Lau, W. C. Y., Man, K. K. C., Chui, C. S. L., & Wong, I. C. K. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023489 · Cited by 16
Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy
McCrimmon, R. J., Lamotte, M., Ramos, M., Alsaleh, A. J. O., Souhami, E., & Lew, E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01156-1 · Cited by 15
Data on effect of Tempeh Fermentation on patients with type II diabetes
Su, H., Tsai, M., Chao, H., Wu, M., & Lu, J. (2021) · Data in Brief · doi:10.1016/j.dib.2021.107310 · Cited by 15
Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis
Zhang, L., Xue, S., Wu, M., & Dan, D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.914587 · Cited by 14
Bioprosthetic heart valve structural degeneration associated with metabolic syndrome: Mitigation with polyoxazoline modification
Abramov, A., Xue, Y., Zakharchenko, A., Kurade, M., Soni, R. K., Levy, R. J., & Ferrari, G. M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219054120 · Cited by 14
Deep-learning-based natural-language-processing models to identify cardiovascular disease hospitalisations of patients with diabetes from routine visits’ text
Guazzo, A., Longato, E., Fadini, G. P., Morieri, M. L., Sparacino, G., & Camillo, B. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-45115-1 · Cited by 14
GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
Furber, E. C., Hyatt, K., Collins, K. A. L., Yu, X., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., O’Farrell, L. S., et al. (2023) · Diabetes · doi:10.2337/db23-0172 · Cited by 16
Non-Insulin Antihyperglycaemic Drugs and Heart Failure: An Overview of Current Evidence from Randomized Controlled Trials
Savarese, G., Schrage, B., Cosentino, F., Lund, L. H., Rosano, G. M. C., Seferovic, P. M., & Butler, J. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12937 · Cited by 14
Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility
Ferrannini, G., Savarese, G., & Rydén, L. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108796 · Cited by 14
How far along are we in revealing the connection between metformin and colorectal cancer?
Berković, M. C., Mikulić, D., Bilić-Čurčić, I., & Mrzljak, A. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i14.1362 · Cited by 14
Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
Fernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 16
Comparison of the Effects of Various Antidiabetic Medication on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
Ha, J., Lim, Y., Kim, M. K., Kwon, H., Song, K., Ko, S., Kang, M. I., Moon, S. D., & Baek, K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1026 · Cited by 14
Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study
Ohara, M., Nagaike, H., Fujikawa, T., Kohata, Y., Ogawa, M., Omachi, T., Sasajima, R., Chiba, H., Ara, T., Sugawara, A., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108999 · Cited by 14
Predictors of Clinical Inertia and Type 2 Diabetes: Assessment of Primary Care Physicians and Their Patients
Isajev, N., Bjegovic-Mikanovic, V. M., Bukumirić, Z., Vrhovac, D., & Lalic, N. M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19084436 · Cited by 14
Effect of metformin on the long non-coding RNA expression levels in type 2 diabetes: an in vitro and clinical trial study
Parvar, S. N., Mirzaei, A., Zare, A. G., Doustimotlagh, A. H., Nikooei, S., Arya, A., & Alipoor, B. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00427-3 · Cited by 14
Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study)
Ishii, H., Nakajima, H., Kamei, N., Niiya, T., Hiyoshi, T., Hiramori, Y., Ohtsu, S., Noto, T., & Shimono, D. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00941-8 · Cited by 14
Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?
Koufakis, T., Metallidis, S., Zebekakis, P. E., Ajjan, R., & Kotsa, K. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820932155 · Cited by 14
Appraisal of Triglyceride-Related Markers as Early Predictors of Metabolic Outcomes in the PREVIEW Lifestyle Intervention: A Controlled Post-hoc Trial
Navas‐Carretero, S., San-Cristóbal, R., Vestentoft, P. S., Brand-Miller, J. C., Jalo, E., Westerterp‐Plantenga, M. S., Simpson, E. J., Handjieva‐Darlenska, T., Stratton, G., Huttunen‐Lenz, M., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.733697 · Cited by 14
CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy
Russo, G. T., Corigliano, G., Arturi, F., Cavallo, M. G., Bette, C., & Mannucci, E. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.01.026 · Cited by 13
The Role of Platelets in Hypoglycemia-Induced Cardiovascular Disease: A Review of the Literature
Ali, A. A. G., Niinuma, S. A., Moin, A. S. M., Atkin, S. L., & Butler, A. E. (2023) · Biomolecules · doi:10.3390/biom13020241 · Cited by 13
Effects of Different Cooking Methods on Glycemic Index, Physicochemical Indexes, and Digestive Characteristics of Two Kinds of Rice
Yao, F., Li, C., Li, J., Chang, G., Wang, Y., Campardelli, R., Perego, P., & Cai, C. (2023) · Processes · doi:10.3390/pr11072167 · Cited by 13
SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease
Wang, M., Cai, X., LIANG, R., Zhang, E.-M., Liang, X.-Q., Liang, H., Fu, C. L., Zhou, A.-D., Shi, Y. Y., Xu, F. L., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115515 · Cited by 14
Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials
Watada, H., Yamauchi, T., Yamamoto, F., Taniguchi, A., Yarush, L., Heilmann, C. J., & Yasui, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1782884 · Cited by 13
Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add‐on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care ( LIRA‐PRIME )
Unger, J., Allison, D. C., Kaltoft, M. S., Lakkole, K., Panda, J. K., Ramesh, C. K., Sargın, M., Smolyarchuk, Е. А., Twine, M., Wolthers, B. O., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14566 · Cited by 13
Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK
McCrimmon, R. J., Falla, E., Sha, J. Z., Alsaleh, A. J. O., Lew, E., Hudson, R. D. A., Baxter, M., & PALMER, K. D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01159-y · Cited by 13
Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes
Luo, J., Gabriel, N., Korytkowski, M. T., Hernandez, I., & Gellad, W. F. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109855 · Cited by 16
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
Schnell, O., Cos, X., Cosentino, F., Forst, T. M., Giorgino, F., Heersprink, H. J. L., Kosiborod, M., Wanner, C., & Standl, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01254-1 · Cited by 13
Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China
Li, C., Guo, S., Huo, J., Gao, Y., Yan, Y., & Zhao, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.987081 · Cited by 12
Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care
O’Hara, D. V., Janse, R. J., Fu, E. L., Jardine, M., & Carrero, J. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111745 · Cited by 13
Diabetes mellitus, vaginal microbiome and sexual function: Outcomes in postmenopausal women
Scairati, R., Auriemma, R. S., Vecchio, G. D., Meglio, S. D., Pirchio, R., Graziadio, C., Pivonello, R., & Colao, A. (2025) · Maturitas · doi:10.1016/j.maturitas.2025.108210 · Cited by 12
The research progress and future directions in the pathophysiological mechanisms of type 2 diabetes mellitus from the perspective of precision medicine
Tian, X., Wang, L., Zhong, L., Zhang, K., Ge, X., Luo, Z., Zhai, X., & Liu, S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1555077 · Cited by 19
Obesidad y SARS-CoV-2: consideraciones sobre la cirugía bariátrica y recomendaciones para el inicio de la actividad quirúrgica
Santos, R. S., de Gordejuela, A. G. R., Lesmes, I. B., Lecube, A., Arcone, V. M., Martín, J. J. A., Alsina, E. F., Antona, E. M., Rubio, M. Á., Sabench, F., et al. (2020) · Cirugía Española · doi:10.1016/j.ciresp.2020.06.005 · Cited by 12
The “Early Treatment” Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique
Russo, G. T., Monami, M., Perseghin, G., Avogaro, A., Filardi, P. P., Senni, M., Borghi, C., & Maggioni, A. P. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01045-7 · Cited by 12
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial
Wharton, S., Yin, P., Burrows, M., Gould, E. M., Blavignac, J., Christensen, R. A. G., Kamran, E., Camacho, F., & Barakat, M. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00831-4 · Cited by 16
Direct medical costs of type 2 diabetes mellitus in the Philippines: findings from two hospital databases and physician surveys
Jimeno, C., Sy, R. A., Pena, P. D., Cipriano, C. C., Tan, R., Panelo, A., & Ng, J. Y. S. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049737 · Cited by 12
Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
Eliasson, B., Ericsson, Å., Fridhammar, A., Nilsson, A., Persson, S., & Chubb, B. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00317-z · Cited by 14
Effects of a Digital Patient Empowerment and Communication Tool on Metabolic Control in People With Type 2 Diabetes: The DeMpower Multicenter Ambispective Study
Orozco‐Beltrán, D., Morales, C., Artola‐Menéndez, S., Brotons, C., Carrascosa, S., González, C., Baró, O., Verdugo, A. A., de Campos, K. F., Villarejo, M., et al. (2022) · JMIR Diabetes · doi:10.2196/40377 · Cited by 19
Synergistic impact of diabetes and cognitive impairment on all-cause and cause-specific mortality in Chinese older adults: A prospective population-based cohort study
Li, Z., Wang, S., Liu, S., Gong, X., Wang, Y., Wu, D., Yang, M., Li, R., Li, H., Li, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.997260 · Cited by 12
Body mass index–based predictions and personalized clinical strategies for colorectal cancer in the context of PPPM
Gu, Y.-J., Chen, L., Gu, M., Xu, H., Li, J., & Wu, L. (2022) · The EPMA Journal · doi:10.1007/s13167-022-00306-0 · Cited by 12
Redox Remodeling by Nutraceuticals for Prevention and Treatment of Acute and Chronic Inflammation
Petrarca, C., & Viola, D. (2023) · Antioxidants · doi:10.3390/antiox12010132 · Cited by 12
Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States
Nargesi, A. A., Clark, C. N., Aminorroaya, A., Chen, L., Liu, M., Reddy, A., Amodeo, S., Oikonomou, E. K., Suchard, M. A., McGuire, D. K., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.03.002 · Cited by 12
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK
Evans, M., Berry, S., Malkin, S. J. P., Hunt, B., & Sharma, A. K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01408-2 · Cited by 12
Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study
Chang, H., Chen, Y., Kuo, T., Lin, Y., Chien, K., Chang, H., Hung, C., & Chung, F. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032397 · Cited by 13
Pharmaceutical Analytical Profile for Novel SGL-2 Inhibitor: Dapagliflozin
Ganorkar, S. B., Sharma, S. S., Patil, M. R., Bobade, P. S., Dhote, A. M., & Shirkhedkar, A. A. (2020) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2020.1777524 · Cited by 12
Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
Chiba, K., Nomoto, H., Nakamura, A., Cho, K. Y., Yamashita, K., Shibayama, Y., Miya, A., Kameda, H., Kurihara, Y., Aoki, S., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13335 · Cited by 12
Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study
Morieri, M. L., Targher, G., Lapolla, A., D'Ambrosio, M., Tadiotto, F., Rigato, M., Frison, V., Paccagnella, A., Simioni, N., Avogaro, A., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.049 · Cited by 13
Teucrium polium: Potential Drug Source for Type 2 Diabetes Mellitus
Albadr, Y., Crowe, A. P., & Caccetta, R. (2022) · Biology · doi:10.3390/biology11010128 · Cited by 12
Low Carbohydrate Diets for Diabetic Cardiomyopathy: A Hypothesis
Kleissl-Muir, S., Rasmussen, B., Owen, A. J., Zinn, C., & Driscoll, A. L. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.865489 · Cited by 12
The occurrence of drug-induced side effects in women and men with arterial hypertension and comorbidities
Polaczyk, M., Olszanecka, A., Wojciechowska, W., Rajzer, M. W., & Stolarz‐Skrzypek, K. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0232 · Cited by 12
Treatment options following metformin in primary prevention populations with type 2 diabetes: which is the right road to take?
Koufakis, T., Παπάνας, Ν., Zebekakis, P. E., & Kotsa, K. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1942843 · Cited by 12
Disparities in adoption of new diabetic therapies with cardiovascular benefits
Vasti, E. C., Basina, M., Calma, J., Maron, D. J., Rodriguez, F., & Sandhu, A. T. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110233 · Cited by 11
Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives
Салухов, В. В., Galstyan, G. R., & Ilyinskaya, Т. A. (2022) · Diabetes Mellitus · doi:10.14341/dm12855 · Cited by 13
A cross‐sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa ( PACT‐MEA ): Study design and rationale
Verma, S., Sabbour, H. M., Alamuddin, N., Alawadi, F., Alkandari, H., Almahmeed, W. A., Assaad-Khalil, S. H., HADDAD, J. A., Lombard, L., Malik, R. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15011 · Cited by 11
Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus
Alqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis
Talamonti, E., Davegardh, J., Kalinovich, A., van Beek, S. M. M., Dehvari, N., Halleskog, C., Bokhari, M. H., Hutchinson, D. S., Ham, S., Humphrys, L. J., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101931 · Cited by 10
Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies
Morissette, A., & Mulvihill, E. E. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.012 · Cited by 12
Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus
Patoulias, D., Papadopoulos, C. E., Katsimardou, A., Kalogirou, M., & Doumas, M. N. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.08.002 · Cited by 11
Improving frequency of urinary albumin testing in type 2 diabetes in primary care — An analysis of cross-sectional studies in Denmark
Persson, F., Charles, M., Povlsen, J. V., & Knudsen, S. T. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.07.003 · Cited by 11
Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies
Feng, W., Wang, W., Meng, R., Wu, G., Zhang, M., Zhang, X., Yin, H., & Zhu, D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002290 · Cited by 11
Alternative treatments for type 2 diabetes and associated metabolic diseases: medical therapy or endoscopic duodenal mucosal remodelling?
van Baar, A. C. G., Meiring, S., Holleman, F., Hopkins, D., Mingrone, G., Deviere, J. M. E., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2021) · Gut · doi:10.1136/gutjnl-2020-323931 · Cited by 12
Self-citation
Fixed‐ratio combination of insulin glargine plus lixisenatide ( iGlarLixi ) improves ß‐cell function in people with type 2 diabetes
Ferrannini, E., Niemoeller, E., DEX, T. A., Servera, S., & Mari, A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14688 · Cited by 11
The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials
Franch‐Nadal, J., Malkin, S. J. P., Hunt, B., Martín, V., Estébanez, M. G., & Vidal, J. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02156-8 · Cited by 11
Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis
Memon, R. A., Akbariromani, H., Vohra, R. R., Kundi, H., Saleem, F., Ghaffari, M. A. Z., Haas, D. C., & Khan, A. (2022) · Cureus · doi:10.7759/cureus.27277 · Cited by 11
Gender-associated cardiometabolic risk profiles and health behaviors in patients with type 2 diabetes: a cross-sectional analysis of the Joint Asia Diabetes Evaluation (JADE) program
Lim, L., Lau, E. S. H., Kong, A. P. S., Fu, A. W. C., Lau, V., Jia, W., Sheu, W. H., Sobrepeña, L., Yoon, K., Tan, A. T. B., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100663 · Cited by 12
SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies
Ma, Y., Zhao, Q., Peng, H., Nalisa, D. L., Shan, P., & Jiang, H. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2805098 · Cited by 11
Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤ 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials
Lv, Q., Shen, J., Miao, L., Ye, B., Schepers, C., Plat, A. W., & Shi, Y. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00819-9 · Cited by 14
Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
MacIsaac, R. J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00863-5 · Cited by 11
Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region
Qiu, M., Ding, L., Xu-bin, W., Wei, W., & Zhou, H. (2020) · Medicine · doi:10.1097/md.0000000000023489 · Cited by 11
Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis
Lautsch, D., Alsumali, A., McLeod, E. J., Kuang, Y., He, J. N., Singh, R., Nevo, A., Arnet, U. A., Uyei, J., & Rajpathak, S. N. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00975-y · Cited by 12
TYK2 Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients
Mori, H., Takahashi, H., Mine, K., Higashimoto, K., Inoue, K., Kojima, M., Kuroki, S., Eguchi, T., Ono, Y., Inuzuka, S., et al. (2021) · Genes · doi:10.3390/genes12030400 · Cited by 10
Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Nowrouzi‐Sohrabi, P., Soroush, N., Tabrizi, R., Shabani-Borujeni, M., Rezaei, S., Jafari, F. M., Hosseini‐Bensenjan, M., Stricker, B. H. C., van Hoek, M., & Ahmadizar, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618208 · Cited by 11
The evolution and future of diabetic kidney disease research: a bibliometric analysis
Wei, Y., & Jiang, Z. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02369-z · Cited by 11
The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for metformin: a systematic review and meta-analysis of randomized controlled trials
Li, X., Zhang, Q., Zhou, X., Guo, S., Jiang, S., Zhang, Y., Zhang, R., Dong, J., & Liao, L. (2021) · Aging · doi:10.18632/aging.202945 · Cited by 11
Serum netrin and VCAM-1 as biomarker for Egyptian patients with type IΙ diabetes mellitus
Fadel, M. M., Ghaffar, F. R. A., Zwain, S. K., Ibrahim, H. M., & Badr, E. A. E. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101045 · Cited by 11
Resumen ejecutivo sobre el tratamiento de la diabetes mellitus tipo 2 en personas de edad avanzada o frágiles. Actualización 2022 del documento de consenso 2018 «Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano»
Peralta, F. G., Carrasco-Sánchez, F. J., Pérez, A., Escalada, J., Guisasola, F. Á., Fernández-Santos, C. M., Bravo, J. J. M., & Gómez‐Huelgas, R. (2022) · Revista Clínica Española · doi:10.1016/j.rce.2022.03.004 · Cited by 11
A combination of metformin and insulin improve cardiovascular and cerebrovascular risk factors in individuals with type 1 diabetes mellitus
Xu, L., Wang, W., & Song, W. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110073 · Cited by 11

Authors: Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J.
Affiliations: University of North Carolina at Chapel Hill (US)
Harvard University (US)
Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
University of Copenhagen (DK)
Università Cattolica del Sacro Cuore (IT)
Universitair Ziekenhuis Leuven (BE)
Duke University (US)
University of Leicester (GB)
Corresponding author: Davies, Melanie J.
ORCID: Buse, John B.
Wexler, Deborah J.
Tsapas, Apostolos
Rossing, Peter
Mingrone, Geltrude
Mathieu, Chantal
D’Alessio, David A.
Davies, Melanie J.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2019-12-19
Volume: 43
Issue: 2
Pages: 487-493
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dci19-0066
PMC: PMC6971782
OpenAlex: W4253996779
Cited by: 1,192
References: 21
Citations by year: 2026: 54 · 2025: 79 · 2024: 128 · 2023: 162 · 2022: 277 · 2021: 279 · 2020: 212
FWCI: 155.76
Type: journal article
Language: en
Update notices: correction (2020-07-01)
Open access: bronze
doi.org
Licence: www.diabetesjournals.org/content/license (vor, 32 d)
Locations: Diabetes Care (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
Lirias (submittedVersion)
PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
Funders: American Diabetes Association
European Association for the Study of Diabetes
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: hyperglycemia management, type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors, major adverse cardiovascular events, heart failure hospitalization, heart failure with reduced ejection fraction, chronic kidney disease progression, HbA1c targets, cardiovascular risk stratification

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks